Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Marimed (MRMD) Long-Term Debt Repayments (2016 - 2025)

Marimed has reported Long-Term Debt Repayments over the past 8 years, most recently at $1.5 million for Q4 2025.

  • Quarterly Long-Term Debt Repayments changed N/A to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $6.1 million for FY2025, N/A changed from the prior year.
  • Long-Term Debt Repayments was $1.5 million for Q4 2025 at Marimed, roughly flat from $1.5 million in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $15.3 million in Q2 2021 and troughed at $2294.0 in Q3 2021.
  • The 3-year median for Long-Term Debt Repayments is $1.5 million (2025), against an average of $3.1 million.
  • The largest YoY upside for Long-Term Debt Repayments was 2086.0% in 2021 against a maximum downside of 99.54% in 2021.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $619727.0 in 2021, then soared by 787.97% to $5.5 million in 2023, then plummeted by 72.74% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Long-Term Debt Repayments are $1.5 million (Q4 2025), $1.5 million (Q3 2025), and $1.6 million (Q2 2025).